An interventional study of UV-Photofunctionalized Dental Implant and Conventional Dental Implant in Jaw, Edentulous, Partially, Bone Resorption and Dental Implant Failure, sponsored by Mansoura University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-02.
Sponsored by Mansoura University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate and compare the clinical and radiographic outcomes of using photofunctionalized (UV-treated) dental implants with or without the application of melatonin hormone in the posterior maxilla (upper back jaw).
The posterior maxilla is known to have lower bone quality, which can negatively affect the primary and secondary stability of dental implants,. UV photofunctionalization is a method that modifies the titanium surface of the implant, changing it from hydrophobic (water-repelling) to superhydrophilic (water-attracting). This enhancement aims to accelerate protein adsorption and promote bone-building cells (osteoblasts). On the other hand, melatonin acts as an anti-inflammatory and antioxidant agent that stimulates bone formation and reduces bone resorption.
A total of 21 dental implants will be placed in patients requiring tooth replacement in the posterior maxilla. The implants will be divided into three main approaches: one using UV-treated implants alone, and the other combining UV-treated implants with melatonin. and one using conventional implant Patients will be followed up clinically and radiographically to assess implant stability, bone healing, and overall implant success over time.
This interventional study is designed to clinically and radiographically evaluate the potential synergistic effects of ultraviolet (UV) photofunctionalized dental implants combined with melatonin hormone in the posterior maxilla, bone density (D4 bone quality) and challenging primary implant stability.
Biological aging of titanium is an unavoidable phenomenon occurring within weeks of manufacturing, where hydrocarbon contamination covers the protective titanium dioxide layer, increasing surface hydrophobicity and reducing optimal osteoblast adhesion. To counteract this, UV photofunctionalization (UV irradiation) will be utilized immediately prior to implant insertion to restore superhydrophilic properties, reduce hydrocarbon content, and enhance early protein adsorption and osteoblastic differentiation.
Additionally, melatonin (N-acetyl-5-methoxytryptamine) will be investigated as an alternative graft or bioactive material. Melatonin exhibits potent anti-inflammatory and antioxidant capabilities, destroys reactive oxygen species, and stimulates human osteoblasts to synthesize type I collagen fibers. It also down-regulates RANKL-mediated osteoclast activation, thereby reducing bone resorption during the critical early healing phases.
Patients will be selected from the Outpatient Clinic of the Oral and Maxillofacial Surgery Department, Faculty of Dentistry, Mansoura University, following ethical committee approval and obtaining informed written consents. A total of 21 implants will be placed in the posterior maxilla. The clinical and radiographic evaluation will monitor parameters such as primary and secondary implant stability, marginal bone level changes, and peri-implant tissue health to compare the outcomes of photofunctionalized implants alone against those combined with melatonin.
76 studies on the registry are indexed under Jaw, Edentulous, Partially; 7 are open to participants now.
This study's planned enrollment of 21 is below the median of 38 across 67 interventional studies indexed under Jaw, Edentulous, Partially.
Browse Jaw, Edentulous, Partially studies →Mansoura University is the lead sponsor of 1,121 studies on the registry; 183 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients in this group will receive ultraviolet (UV) photofunctionalized dental implants combined with the topical application of melatonin hormone at the implant site in the posterior maxilla to evaluate early bone formation.
Device: UV-Photofunctionalized Dental Implant
Patients in this group will receive ultraviolet (UV) photofunctionalized dental implants alone without the application of melatonin hormone in the posterior maxilla to serve as the active control group.
Device: UV-Photofunctionalized Dental Implant
Patients in this group will receive conventional titanium dental implants in the posterior maxilla to serve as the baseline control group.
Device: Conventional Dental Implant
Commercial titanium dental implants subjected to ultraviolet (UV) light irradiation immediately prior to surgical placement to convert the surface property from hydrophobic to superhydrophilic.
Standard commercial titanium dental implants placed using traditional surgical protocols without any UV surface photofunctionalization or melatonin application.
Implant Stability (ISQ)
Implant stability will be measured using Resonance Frequency Analysis (RFA) to obtain the Implant Stability Quotient (ISQ) value. Higher ISQ values indicate greater primary and secondary implant stability.
Time frame: At the time of implant placement (baseline), 2, 4, weeks, 3 and 9 months
Marginal Bone Level Changes
Radiographic evaluation using standardized digital periapical radiographs to measure peri-implant marginal bone loss or gain in millimeters.
Time frame: At the time of implant placement (baseline), 3 months, and 9 months post-operatively.
Plan to share: Undecided
Started Feb 2026 (actual). Primary completion is estimated for Nov 2026, 9 months after the start.
Of 34 interventional studies with no phase under Jaw, Edentulous, Partially, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 61. This study's planned 9 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.